NCT06691243View on ClinicalTrials.gov

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

March 31, 2027

Conditions
Cocaine Use DisorderHIV
Interventions
DRUG

Semaglutide

The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.

DRUG

Placebo

Patients randomized to placebo arm will receive placebo injection every week.

Trial Locations (2)

20002

RECRUITING

Institute of Human Virology at the University of Maryland School of Medicine, Washington D.C.

21201

RECRUITING

Institute of Human Virology at the University of Maryland School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT06691243 - Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Biotech Hunter | Biotech Hunter